Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecvayli
teclistamab-cqyv · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Optional 1.5 mg/kg every two weeks for patients in the approved relapsed or refractory multiple myeloma setting who maintain complete response or better for at least six months.
LAMPGEN ANALYSIS
Why it matters
The approved interval can reduce treatment visits for patients who meet the sustained response criterion.
What research teams should watch
Confirm the response start date and duration before changing the orders, and preserve infection and immunoglobulin follow-up.
PRIMARY RECORDS